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Abstract
Little is known about the nature of foamy virus (FV) receptor molecules on target cells and their interaction with the viral glycoproteins.
Similar to other viruses, cellular expression of the FV Env protein is sufficient to induce resistance to exogenous FV, a phenomenon called
superinfection resistance (SIR). In this study we define determinants of the FV Env protein essential for mediating SIR. FV Env requires
the extracellular domains of the SU and the TM subunits as well as membrane anchorage, efficient cell surface transport, and most probably
correct subunit processing. This is in contrast to murine leukemia virus where secreted proteins comprising the receptor-binding domain in
SU are sufficient to induce SIR. Furthermore, we demonstrate that cellular expression of the prototype FV envelope proteins induces SIR
against pseudotypes with glycoproteins of other FV species, including of simian, feline, bovine, and equine origin. This implies that all of
them use the same receptor molecules for viral entry.
© 2003 Elsevier Science (USA). All rights reserved.
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Introduction
The envelope glycoprotein of retroviruses is synthesized
as a precursor molecule in infected cells (reviewed in Swan-
strom and Wills, 1997). Cleavage of the precursor by a
cellular protease into a larger extracellular surface (SU) and
a smaller transmembrane (TM) domain takes place in the
course of its transport to the cell surface. Subsequently
envelope oligomers of this heterodimer, mostly trimers, are
incorporated into the viral particle during the budding pro-
cess. The SU domain mediates attachment of the viral par-
ticle to the cell surface of target cells by specific recognition
of receptor molecules (reviewed in Hunter, 1997). The TM
domain contains the machinery required for fusion of viral
and cellular lipid membranes to release the viral capsid into
the cytoplasm.
Infection by exogenous virus can be blocked by expres-
sion of envelope protein from the target cell. This barrier to
infection, termed superinfection exclusion or superinfection
resistance (SIR), is thought to be mediated by interactions
between the envelope protein and its receptor either intra-
cellularly or at the cell surface (Delwart and Panganiban,
1989; Heard and Danos, 1991; Sommerfelt and Weiss,
1990; Stevenson et al., 1988). Several retroviruses, includ-
ing murine leukemia virus (MuLV), human immunodefi-
ciency virus (HIV), and reticuloendotheliosis virus, use
Env-mediated superinfection resistance mechanisms (Del-
wart and Panganiban, 1989; Heard and Danos, 1991; Som-
merfelt and Weiss, 1990; Stevenson et al., 1988), although
some of them have developed and utilize additional non-
Env-mediated mechanisms to prevent superinfection (re-
viewed in Potash and Volsky, 1998). In contrast, cellular
expression of mouse mammary tumor virus (MMTV) en-
velope protein does not prevent superinfection in vitro or in
vivo, although high levels of exogenously added recombi-
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nant MMTV SU protein were able to block infection
(Dzuris et al., 1999). For MuLV it has been shown that
cellular expression of the Env SU subunit or even a small
subdomain of SU is sufficient to mediate SIR in vitro
(Battini et al., 1995; Heard and Danos, 1991). Among others
this principle has been used as a tool to define the receptor-
binding domain (RBD) of MuLV in greater detail.
Foamy viruses (FV) are a special group of retroviruses.
They have been identified in numerous species (reviewed in
Falcone et al., 2003; Saib, 2003) and for some of them
infectious molecular clones have been isolated (Helps and
Harbour, 1997; Mergia and Wu, 1998; Renshaw et al.,
1991; Rethwilm et al., 1990; Tobaly-Tapiero et al., 2000).
They display many unique features in their replication cycle
not found for any other retrovirus (reviewed in Linial,
1999). The particle associated Env protein of FV is synthe-
sized as a 130-kDa precursor protein. Similar to other ret-
roviral glycoproteins it is processed by a cellular most likely
furinlike protease into an 80- to 90-kDa SU and a 48-kDa
TM domain and is thought to adopt a trimeric oligomeric
structure at the cell surface and in viral particles (Wilk et al.,
2000). Unique to FVs is the incorporation of a third cleav-
age product into the viral particle, the N-terminal leader
peptide (LP) (Lindemann et al., 2001; Wilk et al., 2001).
The LP harbors in its N-terminal cytoplasmic region the
so-called budding domain that interacts with the FV capsid
during particle egress (Lindemann et al., 2001; Wilk et al.,
2001). Unlike as reported for other retroviruses, Gag ex-
pression is not sufficient for generation of foamy viruslike
particles (VLP) secretion into the supernatant (Baldwin and
Linial, 1998; Fischer et al., 1998). FVs require coexpression
of their cognate Env protein containing a functional budding
domain for particle release (Lindemann et al., 2001;
Pietschmann et al., 1999).
FVs have a very broad host range and to date no cell type
has been identified that is refractory to infection by FV or
FV Env pseudotypes (reviewed in Hooks and Gibbs, 1975;
Lindemann et al., 1999). Little is known about the nature of
receptor(s) to which FVs bind at the cell surface of target
cells. Like other retroviruses, FV Env expression in cells
results in resistance toward infection with FVs (Herchen-
ro¨der et al., 1999; Hill et al., 1999; Moebes et al., 1997). In
this study, we characterized determinants of the prototype
FV (PFV), formerly known as human FV (HFV), Env
protein that are required for mediating SIR and analyzed
whether it induces resistance toward entry mediated by
heterologous Envs of other FV species.
Results and discussion
Establishment of a FV Env mediated superinfection assay
It has been reported previously that cells expressing
stably PFV Env are resistant to infection with PFV (Herch-
enro¨der et al., 1999; Hill et al., 1999; Moebes et al., 1997).
In order to analyze the determinants of the PFV glycopro-
tein required for induction of SIR we established a quanti-
tative assay schematically outlined in Fig. 1. It is based on
the generation of a stably glycoprotein expressing cell pop-
ulation by retroviral vector transduction followed by selec-
tion of a coexpressed EGFP-Zeocin (EGZ) marker gene in
a first step. When analyzed by FACS the HT1080 cell
populations obtained by this method contained more than
96% EGZ-positive cells. In a second step a defined number
of Env-expressing cells was challenged with pretitrated,
human CD8- (hCD8) expressing MuLV vectors
pseudotyped with various viral glycoproteins. Subse-
quently, the percentage of transduced cells is determined by
anti-CD8 antibody staining and FACS analysis from which
the relative SIR compared to a control cell population is
calculated. First we validated the assay using the ampho-
tropic MuLV (MLV-A) envelope protein and determined
whether we could obtain SIR levels similar to those reported
in the literature (Battini et al., 1995, 1998; Granowitz et al.,
1991). Therefore we generated cell populations expressing
the wild-type PFV Env, the MLV-A Env, or the empty
retroviral vector. Expression of the respective Env proteins
could be detected by Western blot analysis in the Zeocin-
resistant cell populations (Fig. 2A). Subsequently, individ-
ual cell populations were challenged with hCD8 expressing
MuLV vectors pseudotyped either by vesicular stomatitis
virus glycoprotein G (VSV-G), MLV-A Env, or the PFV
Env and the relative SIR toward the challenge virus was
calculated using HT1080 wild-type cells as standard. As
expected, only MLV-A Env-expressing cells were resistant
toward infection with MLV-A MuLV pseudotypes, whereas
all other cell populations, including PFV Env-expressing
cells, were readily transduced (Fig. 2B). Similarly, only
PFV Env-expressing cells were resistant to a challenge with
PFV Env-pseudotyped MuLV vectors (Fig. 2B). No differ-
ence in susceptibility of the different cell populations to-
ward VSV-G pseudotypes could be observed. Both MLV-A
and PFV glycoprotein expressing cell populations showed
SIR levels in the range of two orders of magnitude toward
pseudotypes with the same glycoprotein. For MuLV this is
in a similar range as reported in the literature (Battini et al.,
1995, 1998). Furthermore, these results not only confirmed
previous reports (Herchenro¨der et al., 1999; Hill et al.,
1999; Moebes et al., 1997) that PFV Env by itself is able to
induce SIR but, in addition, demonstrated that it can do so
at levels comparable to other retroviral glycoproteins. Fi-
nally, they demonstrate that PFV Env does not induce SIR
to unrelated heterologous glycoproteins such as MLV-A
and VSV-G.
Membrane anchorage of PFV Env extracellular domains
is required to induce superinfection resistance
For MuLV it has been reported that secretion of the
envelope SU subunit by cells is sufficient to induce SIR
(Battini et al., 1995). To analyze whether analogous to that
FV Env extracellular domains, in particular the SU subunit,
are sufficient to induce SIR, we generated cell populations
244 A. Berg et al. / Virology 314 (2003) 243–252
expressing several previously biochemically characterized
C-terminal FV Env truncation mutants (Pietschmann et al.,
1999) and analyzed them in the SIR assay (Fig. 3). All
proteins were expressed at similar levels in the selected cell
populations (Fig. 3B). A small deletion at the C-terminus of
the cytoplasmic domain (CyD) (HFE-1) had no significant
influence, whereas complete deletion of the CyD (HFE-2)
resulted in a 10-fold reduced resistance (Fig. 3A). Further
deletion of the membrane-spanning domain (MSD), leading
to a secreted FV Env protein containing the extracellular
domains of SU and TM (HFE-3) (Pietschmann et al., 1999),
resulted in another drop in SIR, about 30-fold, compared to
the wild-type FV Env protein (Fig. 3A). Artificial mem-
brane anchorage of the HFE-3 protein by addition of a
phosphoinositol anchor signal sequence (HFE-3-Pi) re-
stored SIR to almost wild-type levels (Fig. 3A). Expression
of a secreted FV SU subunit (HFE-4) failed to induce any
detectable SIR, and in contrast to the HFE-3 protein artifi-
cial membrane association of the SU subunit (HFE-4) by a
phosphoinositol anchor (HFE-4-Pi) resulted in SIR levels
only marginally above background (Fig. 3A).
Taken together, these data indicate that, in contrast to the
MuLV Env glycoprotein, secretion of the FV Env SU sub-
unit is not sufficient to promote SIR. For induction of SIR
by the PFV Env protein the extracellular domains of the TM
subunit are also required in secreted proteins and additional
membrane anchorage enhances the efficiency of SIR in-
duced by such proteins. The determinants for an oligomeric
structure of retroviral glycoproteins are normally located in
the extracellular domains of the TM subunit (reviewed in
Hunter, 1997; Swanstrom and Wills, 1997). Individually
expressed SU subunits are generally monomers. Therefore,
Fig. 1. Schematical outline of the superinfection resistance assay. The generation and analysis of FV mutant Env-expressing cells is shown. Viral
glycoprotein-expressing cell populations are generated by transduction of VSV-G pseudotyped MuLV retroviral vectors carrying a bicistronic expression
cassettes for different viral glycoproteins and an EGFP-Zeocin (EGZ) selection marker, followed by Zeocin selection for 10 days. Subsequently, equal
numbers of the EGZ resistant cell populations are challenged with FV Env MuLV retroviral vector pseudotypes carrying an expression cassette for the human
CD8 cell surface protein (hCD8). Two days later the percentage of CD8 expressing cells in the different populations was determined by anti-CD8
immunostaining and FACS. The relative superinfection resistance (SIR) level was calculated by dividing the percentage of CD8/EGZ control cells (e.g.,
MuLV ampho Env-expressing cells) infected with a given pseudotyped vector by the percentage of CD8/EGZ cells of the respective FV Env-expressing
cells (e.g., FV Env wt-expressing cells or FV Env mutant-expressing cells).
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these results suggest that oligomeric organization of the FV
Env protein is required for a strong interaction with the
cellular receptor molecules to induce SIR and that mono-
mers form only weak interactions, insufficient to induce
SIR. This is in line with the observation that a chimeric
protein of the SU domain of the chimpanzee FV isolate
(SFVcpz) and the Fc fragment of human IgG1 heavy chain
specifically binds to cells (Herchenro¨der et al., 1999). How-
ever, dose–response curves yielded no saturation of cellular
binding sites by this chimera and furthermore pretreatment
of target cells with this protein was not able to prevent
infection with exogenous FV (Herchenro¨der et al., 1999).
Efficient cell surface transport is required for induction of
superinfection resistance
SIR is thought to be mediated by interactions between
the envelope protein and its receptor either intracellularly or
at the cell surface (Delwart and Panganiban, 1989; Heard
and Danos, 1991; Sommerfelt and Weiss, 1990; Stevenson
et al., 1988). In order to distinguish where the interaction
between FV Env and its putative receptor occurs we ana-
lyzed some previously described chimeric FV Env proteins
that display different intracellular transport characteristics
(Pietschmann et al., 1999). These chimeric FV Env proteins
contain certain domains of MuLV Env, for example, parts
of MSD and/or CyD (Pietschmann et al., 1999). One of
these proteins, HFME-2, having the FV MSD domain re-
placed by that of MuLV, showed a transport defect, result-
ing in a strong intracellular retention (Pietschmann et al.,
1999). In order to determine whether the endoplasmic re-
ticulum (ER) retrieval signal located in the FV Env CyD
(Goepfert et al., 1997; Goepfert et al., 1995) is responsible
for this transport defect we generated two new chimeras
based on HFME-2 with either the FV CyD completely
removed (HFME-3) or an inactivated FV ER retrieval signal
by point mutations (HFME-2SSS) (Fig. 4A). For analysis of
cell surface transport, HT1080 cell populations stably ex-
pressing the different HFME proteins were metabolically
labeled. Subsequently, cell surface proteins were specifi-
cally biotinylated followed by cell lysis and immunopre-
cipitation with a chimpanzee serum recognizing all PFV
proteins. The precipitates were separated by sodium dode-
cyl sulfate–polyacrylamide gel electrophoresis (SDS–
PAGE) and envelope cell surface expression was detected
by Western blot using Streptavidin-HRP. Total cellular Env
expression was analyzed afterwards by autoradiography.
The HFME-2SSS and HFME-3 were efficiently processed
into SU and TM subunits and transported to the cell surface,
even more efficiently than the HFME-1 and the wild-type
PFV Env protein (Fig. 5A). In contrast to that, only a small
amount of biotinylated, uncleaved precursor protein was
detectable for the HFME-2 mutant (Fig. 5A). This biochem-
ical analysis revealed that an intact FV ER retrieval signal is
essential for blocking intracellular transport of the HFME-2
protein. Next, these cell populations were analyzed in the
SIR assay to determine whether cell surface transport is a
prerequisite for induction of FV Env-mediated SIR (Fig. 4).
All chimeric proteins that showed normal cell surface trans-
port and SU/TM processing (Fig. 5), namely HFME-1,
HFME-2SSS, and HFME-3, did induce SIR at wild-type
levels or slightly below (Fig. 4A). Although the HFME-2
protein was expressed intracellularly at comparable levels to
the other chimeras (Fig. 4B and Fig. 5B), it displayed a
strongly reduced cell surface expression (Fig. 5A) and did
not mediate SIR toward the FV Env challenge pseudotype
(Fig. 4A).
Fig. 2. Superinfection resistance of PFV and MuLV Env expressing
HT1080 cells. (A) Glycoprotein expression analysis by Western blot using
PFV Env (anti-PFV LP) or MuLV Env (anti-MLV gp70) specific antisera.
(B) Different HT1080 cell populations as indicated were challenged with
VSV-G (open bars), MLV-A Env (hatched bars) or PFV Env MuLV
pseudotypes (solid bars) expressing the hCD8 protein. The SIR relative to
uninfected wild-type cells was calculated as described under Material and
Methods. Mean values and standard deviation of five experiments are
shown.
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Taken together these data indicate that the ER retrieval
signal of the HFME-2 chimera plays an essential role in the
intracellular retention of the protein. As we demonstrated
previously, this is in contrast to the wild-type FV protein,
whose inactivation has an influence on intracellular distri-
bution of the protein but not on cell surface expression
(Pietschmann et al., 2000). Furthermore, the analysis sug-
gests that a correct intracellular transport is essential for the
interaction of the FV Env with the putative receptor or other
cellular components required for induction of SIR to take
place. From previous experiments addressing carbohydrate
maturation during the intracellular transport by glycosidase
treatment, it is known that the HFME-2 protein accumulates
somewhere prior to reaching the trans-Golgi network
(TGN) (Pietschmann et al., 1999). Therefore, one possible
explanation for the failure of HFME-2 to induce SIR might
be that the Env protein and/or the receptor molecules are in
a conformation that does not allow for an interaction be-
tween both of them during the passage of the early com-
partments of the secretory pathway. Alternatively, it might
be possible that Env protein and receptor molecules meet
only in late secretory compartments such as the TGN. As
the HFME-2 mutant reaches this compartment very ineffi-
ciently no SIR can be induced. However, without knowl-
edge of the FV receptor molecules it is difficult to tell which
explanation holds true.
Correct FV Env subunit processing is required for
induction of superinfection resistance
Because the HFME-2 mutant also showed, in addition to
the strongly reduced cell surface transport, a defect in sub-
unit processing (Figs. 4 and 5 and Pietschmann et al., 1999),
we further analyzed some previously characterized FV Env
mutants showing inhibition of subunit cleavage in respect to
their ability to induce SIR (Lindemann et al., 2001;
Pietschmann et al., 2000). The SU/TM cleavage mutant
EM20 showed normal LP/SU, but no SU/TM proteolysis,
whereas the LP/SU cleavage mutant EM84 showed strongly
reduced LP/SU and SU/TM processing (Fig. 6). Neither
mutant, nor a newly generated combination mutant of both,
EM117, was able to induce FV Env-specific SIR upon
Fig. 3. Capacity of C-terminal PFV Env truncation mutants to induce superinfection resistance. (A) Different HT1080 cell populations as indicated were
challenged with VSV-G (open bars) or PFV Env MuLV pseudotypes (solid bars) expressing the hCD8 protein. A schematic outline of the structure of the
different glycoproteins expressed in the HT1080 cell populations is shown to the left. The mean values and standard deviation of SIR relative to MLV-A
Env-expressing cells of three experiments are shown. (B) Glycoprotein expression analysis by Western blot using a PFV Env LP specific antiserum. The
leader peptide-specific antiserum detects in PFV Env-expressing cell lysates the precursor protein (gp130Env) as well as unglycosylated (p14LP) and
glycosylated (gp18LP) forms of the leader peptide cleavage product (Lindemann et al., 2001). LP, leader peptide; SU, surface domain; TM, transmembrane
domain; CyD, cytoplasmic domain; Pi, phosphoinositol anchor.
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stable expression in HT1080 cells (Fig. 6). EM84 and the
double mutant EM117, however, showed a strongly reduced
cell surface expression, and the single mutant EM20 had a
similar relative cell surface expression level as the wild-type
protein (Fig. 5). Similar to the HFME-1 mutant the overall
expression level of EM20 was somewhat reduced compared
to the wild-type Env protein (Fig. 5). Nevertheless, in con-
trast to the HFME-1 mutant none of the three cleavage
mutants was able to induce SIR upon stable expression in
H1080 cells (Fig. 6), indicating that subunit processing
seems to be a prerequisite for FV Env mediated induction of
SIR.
The failure of the SU/TM cleavage mutant to induce SIR
suggests that subunit processing is required for an efficient
interaction with the cellular receptor molecules. However,
as the EM20 mutant also displays a somewhat reduced cell
surface expression and particle release (Pietschmann et al.,
2000) compared to the wild-type protein, both effects, effi-
cient cell surface transport and subunit processing, cannot
be completely separated. Mutants affecting the LP/SU
cleavage show a strongly reduced cell surface expression
and support the findings with the HFME-2 mutants. This
indicates that normal cell surface transport is required for
induction of FV Env-mediated SIR.
PFV Env expressing cells are resistant toward
pseudotypes with Env proteins of other FV species
A special characteristic of FVs is a very broad host range
(reviewed in Hooks and Gibbs, 1975; Lindemann et al.,
1999). Currently no cell line has been identified that is not
infectable by FVs. This is one reason why the cellular
receptor for FV is still unknown (Lindemann et al., 1999).
However, even without knowing the nature of the cellular
receptor, receptor usage by different viruses can be studied
by receptor interference assays (Sommerfelt, 1999). In a
previous study it was shown that baby hamster kidney
(BHK) cells constitutively expressing the PFV Env protein
were resistant to infection against different primate FV
isolates or PFV Env pseudotypes of VSV (Hill et al., 1999).
We have recently generated glycoprotein expression con-
structs of various FV species that efficiently pseudotype
heterologous retroviral capsids (Jarmy G. and Lindemann
D., unpublished and Picard-Maureau et al., 2003). In order
Fig. 4. Analysis of superinfection resistance mediated by various chimeric PFV Env proteins. (A) Different HT1080 cell populations as indicated were
challenged with VSV-G (open bars) or PFV Env MuLV pseudotypes (solid bars) expressing the hCD8 protein. A schematical outline of the structure of the
different chimeric glycoproteins expressed in the HT1080 cell populations is shown to the left [PFV Env sequences (solid boxes); MuLV sequences (open
boxes)]. The mean values and standard deviation of SIR relative to MLV-A Env-expressing cells of three experiments are shown. (B) Glycoprotein expression
analysis by Western blot using a PFV Env LP-specific antiserum. The leader peptide specific antiserum detects in PFV Env expressing cell lysates the
precursor protein (gp130Env) as well as unglycosylated (p14LP) and glycosylated (gp18LP) forms of the leader peptide cleavage product (Lindemann et al.,
2001). LP, leader peptide; TM, transmembrane domain; CyD, cytoplasmic domain; white dot, mutated ER retrieval signal.
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to determine whether FV of other species use the same
receptor on HT1080 cells as PFV, we analyzed wild-type
PFV Env-expressing cells in respect to their SIR toward
MuLV vectors pseudotyped with Env proteins of other FV
species, namely that of SFV-1, FFV, BFV, and EFV. As
shown in Fig. 7 PFV Env-expressing HT1080 cells were
resistant against challenge with all FV Env pseudotypes
tested, whereas their infectivity with VSV-G pseudotypes
was similar to that of wild-type HT1080 cells. This indicates
that FV of different species use the same receptor molecules
on HT1080 cells.
Concluding remarks
In this study we confirmed previous observations that
cells expressing stably PFV Env are resistant to infection
with PFV (Herchenro¨der et al., 1999; Hill et al., 1999;
Moebes et al., 1997). However, in a recent report by Meier-
ing et al. (2000) no SIR was observed in persistently in-
fected erythroleukemia-derived cells producing low levels
of PFV. Although the authors did not analyze viral protein
expression in these cells, in particular that of the Env pro-
tein, and compared it to acutely infected cells or stably Env
expressing cells, the low-level virus production suggests
that they presumably also express only low levels of the
viral glycoprotein. This might account for the failure to
induce SIR. Indeed, this is in line with the observation in
our experiments that reduced expression of the PFV Env
protein, for example, by using a different retroviral vector
backbone, results in significantly lower levels of relative
SIR induction (data not shown).
Furthermore, we have demonstrated in this study that
efficient induction of SIR by expression of the FV Env
protein requires the extracellular domains of the SU and the
TM subunit as well as membrane anchorage, efficient cell
surface transport, and, most probably, correct subunit pro-
cessing. This is in contrast to the MuLV envelope protein
where secreted proteins comprising the RBD are sufficient
to induce SIR. This suggests that the interaction between the
MuLV Env and its receptor are presumably stronger than
between FV SU and its unknown receptor molecules. How-
ever, FVs have a much broader host range than MuLVs and
assuming FVs use related receptor molecules in different
species this might potentially account for a weaker binding
ability. Interestingly, there are other retroviruses with an
apparently broad in vitro host range and yet unknown re-
ceptor molecules, for example, primate T-cell leukemia
viruses (PTLVs). In contrast to FV, preincubation of target
cells with recombinant PTLV SU lg fusion protein or the
SU domain itself is capable of blocking infection by exog-
enous virus (Jassal et al., 2001a, 2001b). This suggests that
a broad host range and the usage of putatively ubiquitous
receptor molecules do not per se exclude an induction of
SIR by addition of exogenously added RBD. The RBD of
PFV Env has, however, not been characterized in much
detail. The similarity of FV Env protein organization to
other retrovirus glycoproteins (Wang and Mulligan, 1999),
the specific binding of the highly homologous SFVcpz SU–
IgG fusion protein to target cells and its reduced binding to
PFV Env-expressing cells (Herchenro¨der et al., 1999) sug-
gest that the FV RBD is located in the SU subunit. How-
ever, a participation of TM domains in receptor or corecep-
tor recognition and binding cannot be formally excluded. So
far no comparison of binding affinities of FV Env proteins
containing different extracellular domains have been re-
ported. Generating further point and deletion mutants in the
extracellular domains of the PFV Env protein, in particular
in the SU subunit, and subsequent analysis by our SIR
resistance assay might allow for the identification of aa
comprising the FV RBD.
Material and methods
Cells
The human kidney cell line 293T (Du Bridge et al.,
1987) and the human fibrosarcoma cell lines HT1080
Fig. 5. Cell surface expression of various FV Env mutants. Different
glycoprotein-expressing HT1080 cell populations as indicated were meta-
bolically labeled and subsequently cell surface proteins were specifically
biotinylated. (A) Following immunoprecipitation with a FV-positive mon-
key serum, SDS–polyacrylamide gel electrophoresis and blotting to nitro-
cellulose membranes, biotinylated FV Env proteins were detected by in-
cubation with Streptavidin-HRP, ECL, and autoradiography. (B)
Subsequently, total cellular Env expression was visualized by autoradiog-
raphy after the chemoluminescence signal was allowed to fade overnight.
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(Rasheed et al., 1974) were cultivated in Eagle’s minimal
essential medium (MEM) and Dulbecco’s modified Eagle’s
medium (DMEM), respectively, supplemented with 10%
fetal calf serum and antibiotics.
Expression constructs
The MuLV Gag/Pol expression construct pHIT60 (So-
neoka et al., 1995), the amphotropic MuLV envelope ex-
pression construct pHIT456 (Cannon et al., 1996), the ve-
sicular stomatitis virus glycoprotein G (VSV-G) expression
plasmid pcVG-wt (Pietschmann et al., 1999), and the
MuLV retroviral vector pczCFG5IEGZ (Dinev et al., 2001)
were described earlier. Envelope expressing retroviral vec-
tors were generated by inserting the coding sequences of the
following previously described glycoproteins or mutants
thereof into the pczCFG5IEGZ vector: MLV-A Env ex-
pressing the amphotropic MuLV Env derived from
pHIT456 (Cannon et al., 1996); PFV Env expressing the
wild-type PFV gp130Env derived from pczHFVenvEM02
(Lindemann and Rethwilm, 1998; Pietschmann et al.,
1999); HFE-1 (982–988), HFE-2 (976–988), HFE-3
(938–988), and HFE-4 (572–988) expressing C-terminal
truncation mutants lacking various parts of the PFV Env
TM subunit (Pietschmann et al., 1999); HFE-3-Pi and HFE-
4-Pi are variants of HFE-3 and HFE-4, respectively, con-
taining a phosphoinositol anchor signal sequence (hPLAP,
aa 497–530) leading to alternative membrane anchorage
(Pietschmann et al., 1999); EM20 expressing a PFV Env
Fig. 6. Analysis of superinfection resistance mediated by various PFV Env subunit cleavage mutants. (A) Different HT1080 cell populations as indicated were
challenged with VSV-G (open bars) or PFV Env MuLV pseudotypes (solid bars) expressing the hCD8 protein. A schematic outline of the structure of the different
glycoproteins expressed in the HT1080 cell populations is shown to the left. The mean values and standard deviation of SIR relative to wild-type HT1080 cells of
three experiments are shown. (B) Glycoprotein expression analysis by Western blot using a PFV Env LP specific antiserum. LP, leader peptide; SU, surface domain;
TM, transmembrane domain; CyD, cytoplasmic domain; arrows, potential subunit cleavage sites; crossed arrow, mutated potential cleavage sites.
Fig. 7. Resistance of PFV Env expressing cells toward challenge with MLV
pseudotyped with glycoproteins of different FV species. Uninfected (white
bars), MLV-A Env- (gray bars) expressing, or PFV Env- (black bars) express-
ing HT1080 cells were challenged with MuLV vectors expressing the hCD8
protein and pseudotyped with glycoproteins of different FV species as indi-
cated on the left. The mean values and standard deviation of SIR relative to
MLV-A Env-expressing cells of three experiments are shown.
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SU/TM cleavage mutant (R571T) (Pietschmann et al., 2000);
EM84 expressing a SP/SU cleavage mutant (G148R) (Lin-
demann et al., 2001); and EM117 expressing a SP/SU and
SU/TM double cleavage mutant (G148R  R571T) by com-
bining EM84 and EM20. HFME-1 has the MSD and CyD of
PFV Env (aa 938–988) replaced by that of MuLV Env (aa
604–684) (Pietschmann et al., 1999); HFME-2 only the FV
Env MSD (aa 938–975) by that of MuLV Env (aa 604–
652) (Pietschmann et al., 1999); HFME-2SSS was gener-
ated by substituting the FV Env CyD (aa 976–988) of
HFME-2 with that of the HFE-SSS mutant (Pietschmann et
al., 1999) and therefore contains the MuLV Env MSD and
a PFV Env CyD with an inactivated ER retrieval signal,
KKK986 to SSS986 mutation (Lindemann et al., 1997);
HFME-3 was generated by deleting the MuLV Env CyD (aa
653–684) of HFME-1 and therefore contains the MuLV
MSD 604-652 and no CyD at all. Details on the cloning
procedures for the individual mutants are available on re-
quest. All Env proteins are shown schematically in the
respective figures.
Generation of viral supernatants, glycoprotein-expressing
cells, and analysis of superinfection resistance
Supernatants containing recombinant viral particles were
generated essentially as described earlier (Lindemann et al.,
1997; Lindemann and Rethwilm, 1998; Soneoka et al.,
1995). MuLV particles were obtained by cotransfection of
293T cells with the MuLV Gag/Pol expression vector
pHIT60, a MuLV retroviral vector, and an Env expression
vector as indicated. The following expression constructs
were used to generate MuLV pseudotypes harboring glyco-
proteins of different FV species: PFV: pczHFVenv EM64,
having the first 60 aa of PFV LP replaced by that of FFV
(Jarmy G. and Lindemann D., unpublished); SFV-1: pc-
iSFV-1envSM01 (Picard-Maureau et al., 2003); FFV: pc-
zFFVenv (Picard-Maureau et al., 2003); BFV: pczBFVenv
(Picard-Maureau et al., 2003); and EFV: pciEFVenv
(Picard-Maureau et al., 2003).
Glycoprotein-expressing cell populations were generated
by transduction with recombinant VSV-G pseudotyped
MuLV retroviral vectors expressing the respective PFV Env
proteins as indicated and an EGFP-Zeo (EGZ) marker gene
(Dinev et al., 2001). Forty-eight hours posttransfection Env-
expressing cells were selected by addition of Zeocin (600
g/ml) to the growth medium. Starting 10 days postselec-
tion the Env-expressing cell populations were analyzed for
SIR by challenge with pretitrated hCD8a expressing MuLV
vectors pseudotyped with various glycoproteins as indi-
cated. Forty-eight hours postchallenge the transduced cell
populations were stained with PE-conjugated anti-hCD8
monoclonal antibody (Caltag) and subsequently analyzed
by flow cytometry to determine the percentage of CD8 and
EGFP double-positive cells. The relative resistance against
each type of pseudotype challenge supernatant was calcu-
lated by dividing the percentage of CD8/EGZ control
cells by the percentage of CD8/EGZ cells of the respec-
tive FV Env-expressing cells. As control cells either unin-
fected or amphotropic MuLV Env- (MLV-A) expressing
cells were used. Pseudotype supernatant dilutions yielding
infection efficiencies of 20–60% on control cells were used.
A schematical outline of the SIR assay is shown in Fig. 1.
Expression analysis
Glycoprotein expression of the transduced cells was an-
alyzed postselection by Western blot using a rabbit serum
specific for the aa 1–86 of the PFV Env leader peptide
(Lindemann et al., 2001) or a goat serum specific for MuLV
Env (Hansen et al., 2000) as described previously. The
leader peptide specific antiserum detects in PFV Env-ex-
pressing cell lysates the precursor protein (gp130Env) as
well as unglycosylated (p14LP) and glycosylated (gp18LP)
forms of the leader peptide cleavage product (Lindemann et
al., 2001). Cell surface expression was analyzed by meta-
bolic labeling of Env-expressing cells and surface biotiny-
lation followed by radioimmunoprecipitation and Western
blot as described previously (Pietschmann et al., 2000).
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